Last reviewed · How we verify
Meningococcal A conjugate vaccine
This vaccine stimulates the immune system to produce antibodies against Neisseria meningitidis serogroup A by presenting the bacterial polysaccharide capsule conjugated to a protein carrier.
This vaccine stimulates the immune system to produce antibodies against Neisseria meningitidis serogroup A by presenting the bacterial polysaccharide capsule conjugated to a protein carrier. Used for Prevention of meningococcal disease caused by Neisseria meningitidis serogroup A.
At a glance
| Generic name | Meningococcal A conjugate vaccine |
|---|---|
| Also known as | MenAfriVac |
| Sponsor | PATH |
| Drug class | Conjugate vaccine |
| Target | Neisseria meningitidis serogroup A polysaccharide capsule |
| Modality | Biologic |
| Therapeutic area | Immunology / Infectious Disease |
| Phase | FDA-approved |
Mechanism of action
The meningococcal A conjugate vaccine contains the polysaccharide capsule from Neisseria meningitidis serogroup A chemically linked to a protein carrier (conjugate). This conjugation enhances immunogenicity by promoting T-cell dependent B-cell responses, leading to robust production of protective antibodies against the meningococcal serogroup A capsule. The vaccine provides both immediate and long-lasting immunity against meningococcal disease caused by serogroup A.
Approved indications
- Prevention of meningococcal disease caused by Neisseria meningitidis serogroup A
Common side effects
- Injection site pain or erythema
- Fever
- Myalgia
- Headache
Key clinical trials
- Phase IV Clinical Study of Immunogenicity of ACYW135 Group Meningococcal Polysaccharide Conjugate Vaccine (CRM197 Vector) (PHASE4)
- Immunogenicity and Safety Study of an Investigational Quadrivalent Meningococcal Conjugate Vaccine Administered in Healthy Children and Adolescents in China (PHASE3)
- Long-Term PF-06651600 for the Treatment of Alopecia Areata (PHASE3)
- Evaluation of the Antibody Persistence Beyond Five Years After Immunization With MenFiveTM (NmCV-5), a Pentavalent Meningococcal ACYWX Conjugate Vaccine
- A Study to Evaluate Safety, Reactogenicity, and Immune Response of GVGH iNTS-TCV Vaccine Against Invasive Nontyphoidal Salmonella Disease and Typhoid Fever in Infants (PHASE2)
- Study of a Quadrivalent Meningococcal Conjugate Vaccine (MenACYW Conjugate Vaccine) Given With Routine Pediatric Vaccines in Healthy Infants and Toddlers in India and the Republic of South Africa (PHASE3)
- Safety and Immunogenicity of an Investigational Pentavalent Meningococcal ABCYW Vaccine Against Meningococcal Disease in Children, Toddlers, and Infants (PHASE1, PHASE2)
- Study of an Investigational Pentavalent Meningococcal ABCYW Vaccine in Adults and Adolescents (PHASE1, PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Meningococcal A conjugate vaccine CI brief — competitive landscape report
- Meningococcal A conjugate vaccine updates RSS · CI watch RSS
- PATH portfolio CI